Karyopharm Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Karyopharm Therapeutics generated cash of -$92,723,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,124,000 last year. Net change in cash is therefore -$83,693,000.
Cash Flow
| 2014 | -51.44M | -67.03M | 113.12M |
|---|---|---|---|
| 2015 | -94.02M | -90.82M | 92.7M |
| 2016 | -84.39M | 24.59M | 51.16M |
| 2017 | -73.71M | 17.10M | 75.74M |
| 2018 | -159.11M | -107.66M | 316.10M |
| 2019 | -190.82M | 78.45M | 124.30M |
| 2020 | -160.23M | -53.68M | 172.08M |
| 2021 | -107.11M | 141.84M | 73.64M |
| 2022 | -149.55M | -104.25M | 193.73M |
| 2023 | -92.72M | 7.94M | 1.12M |
KPTI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 136.88M | 197.44M | 89.12M | 130.68M | 118.73M | 69.48M | 49.66M | 58.35M | 150.60M | 155.97M |
Operating activities | ||||||||||
Net income | -143.09M | -165.29M | -124.08M | -196.27M | -199.59M | -178.40M | -128.98M | -109.57M | -118.18M | -75.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 530K | 621K | 789K | 972K | 974K | 735K | 713K | 717K | 634K | 323K |
Stock-based compensation expense | 21.70M | 35.39M | 29.78M | 24.40M | 15.29M | 0 | 20.40M | 22.28M | 17.05M | 14.24M |
| Deferred income tax benefit | 21.70M | 35.39M | 29.78M | 24.40M | 15.29M | 0 | 20.40M | 22.28M | 17.05M | 14.24M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 20.12M | -5.08M | -9.61M | -5.01M | -7.86M | 0 | 0 | 0 | 0 | 0 |
Inventories | 1.18M | -118K | -1.46M | -2.62M | -346K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 350K | 1.17M | -2.84M | 3.46M | -3.30M | -1.38M | 909K | 945K | -2.42M | 4.49M |
Cash generated by operating activities | -92.72M | -149.55M | -107.11M | -160.23M | -190.82M | -159.11M | -73.71M | -84.39M | -94.02M | -51.44M |
Investing activities | ||||||||||
Purchases Of Investments | -159.15M | -226.01M | -45.22M | -274.57M | -178.48M | -242.81M | -98.37M | -134.7M | -305.19M | -63.79M |
Investments In Property Plant And Equipment | 0 | -118K | -5.71M | -145K | -206K | -2.36M | -62K | -70K | -1.41M | -2.83M |
Acquisitions Net | 0 | 104.25M | 5.5M | 53.54M | -78.65M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 7.94M | -104.25M | 141.84M | -53.68M | 78.45M | -107.66M | 17.10M | 24.59M | -90.82M | -67.03M |
Financing activities | ||||||||||
Common Stock Issued | 1.12M | 189.76M | 9.90M | 161.77M | 46.19M | 145.70M | 74.88M | 50.57M | 92.08M | 112.83M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -60M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.12M | 193.73M | 73.64M | 172.08M | 124.30M | 316.10M | 75.74M | 51.16M | 92.7M | 113.12M |
Net Change In Cash | -83.69M | -60.56M | 108.32M | -41.56M | 11.95M | 49.25M | 19.33M | -8.69M | -92.25M | -5.36M |
Cash at end of period | 53.19M | 136.88M | 197.44M | 89.12M | 130.68M | 118.73M | 68.99M | 49.66M | 58.35M | 150.60M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |